Atossa遗传学 ATOS 深 沪
已收盘 09-19 16:00:00 美东时间
0.8487
-0.031
-3.55%
华盛通- 最 高0.8847
- 今 开0.88
- 成交量 75.03万股
- 最 低 0.8299
- 昨 收 0.8799
- 总市值 1.09亿
- 52周最高 1.66
- 市盈率 静 --
- 换手率 0.58%
- 52周最低 0.5526
- 委 比 -45.76%
- 总股本 1.29亿
- 历史最高 2232.00
- 量 比 1.18
- 振 幅 6.23%
- 历史最低 0.50
- 每 手 1
- 风险率 0.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多西方石油(OXY.US)直言“抓碳”面临融资压力：自愿市场难签长约+封存风险不对称
西方石油公司的高管称，直接空气捕集模式目前不具“银行可融资性”。自愿市场难签长约、封存风险不对称，DAC规模化可谓困难重重。
09-19 07:06
Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services
<p><p><em>增强投资者意识，加强股东互动，扩大目标受众</em></p> <p>Seattle, 2025年9月17日 ( Globe NewsWire ) -- Atossa Therapeutics, Inc. (纳斯达克代码: ATOS) 委托CORE IR 提供投资者关系和沟通服务。</p> <p> </p> <p> </p></p>
09-17 12:00
Netflix to Announce Third Quarter 2025 Financial Results
LOS GATOS, Calif., Sept. 15, 2025 /PRNewswire/ -- Netflix, Inc. (NASDAQ: NFLX) today announced it will post its third quarter 2025 financial results and business outlook on its investor rela...
09-16 00:00
Atossa Therapeutics Announces New Regulatory Strategy
Atossa Therapeutics ( ($ATOS) ) just unveiled an update. On September 8, 2025, ...
09-08 20:59
Tenon Medical's MAINSAIL Study Shows Significant 12-Month Improvements In Pain, Disability, And Fusion Rates With Catamaran SI Joint Fusion System
~ Clinically Significant Patient Outcomes Demonstrate Improvements in Pain (VAS) and Disability (ODI), Along with High Patient Satisfaction and Safety Profile at 12-Month Analysis ~~ 83% of Patients Reaching 12 Month
09-04 20:38
Atossa Therapeutics Receives Nasdaq Non-Compliance Notice
Atossa Therapeutics ( ($ATOS) ) just unveiled an announcement. On February 21, ...
08-22 04:39
Atossa Therapeutics Selects PSI To Manage FDA-Guided (Z)-Endoxifen Dose-Ranging Study In Metastatic Breast Cancer Ahead Of Phase 3
Monotherapy Phase 2 study designed with FDA input; IND expected in Q4 2025Topline results anticipated in 2026 Positions Atossa for transition into registrational Phase 3 developmentSEATTLE, Aug. 20, 2025
08-20 20:31
Atossa Therapeutics Q2 EPS $(0.07) Misses $(0.06) Estimate
Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 20.69 percent. This is a 40 percent decrease over losses of $(0.05) per share
08-12 20:38
Atossa Therapeutics shares are trading higher after the company announced FDA feedback on its proposed dose optimization trial for (Z)-Endoxifen in ER+/HER2- metastatic breast cancer.
Atossa Therapeutics shares are trading higher after the company announced FDA f...
07-29 19:46
姬广绪｜技术系统的在地性重构：从东京通勤梦魇到中国县域骑手的生存智慧
《通勤梦魇：东京地铁与机器的人类学》，迈克尔·菲什著，孟超、桑元峰译，上海人民出版社2025年1月出版，384页，69.00元 迈克尔·菲什在《通勤梦魇：东京地...
06-25 11:46
